Filter By Category
Archives
Share on -
ATIZORAM
Generic Name: ATIZORAM
ABSTRACT -
Atizoram (CP-80633) is a small-molecule phosphodiesterase-4 (PDE4) inhibitor studied for bronchodilatory and anti-inflammatory effects in conditions such as asthma and inflammatory skin disease. Development has been reported as discontinued. The compound has molecular formula C18H24N2O3.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- No approved public dosing regimen is established for routine use.
- Any research dosing should follow protocol-defined safety monitoring.
- Do not use as a substitute for approved asthma or dermatology therapy.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Nausea, diarrhea, abdominal discomfort, or appetite loss
- Headache, dizziness, insomnia, or fatigue
- Weight loss or mood changes may occur with PDE4 inhibition
- Upper respiratory symptoms or cough may occur in respiratory studies
- Hypersensitivity reactions are possible.
ALLERGIC REACTIONS -
Hypersensitivity to Atizoram or related compounds/products may occur. Symptoms may include:
- Immediate urticaria or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing or breathing difficulty
- Dizziness, collapse, or anaphylaxis
Important: Patients who develop an allergic reaction to Atizoram should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Atizoram may interact with certain medicines, protocols, vaccines, clinical conditions, or procedures. Caution is needed with:
- Strong enzyme inducers or inhibitors may alter exposure depending on metabolism.
- Other PDE inhibitors or stimulants may increase adverse effects.
- Corticosteroids, bronchodilators, and immunomodulators require clinical review.
- Investigational combinations should follow protocol guidance.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Use caution in patients with psychiatric history, weight loss, or severe gastrointestinal disease.
- Monitor respiratory status and inflammation symptoms in studies.
- Pregnancy and lactation safety are not established.
- Avoid unsupervised use for asthma symptoms.
WARNINGS –
- Discontinued investigational compound: not approved for routine therapy.
- Acute asthma symptoms require standard rescue treatment and urgent care when severe.
- Severe mood change, allergic reaction, or persistent vomiting requires medical attention.
- Keep out of reach of children.
Share on -
. Developed by